The mechanism by which bone morphogenetic protein 2 indirectly regulates sclerostin expression in osteocytes

doi:10.12307/2022.352

Abstract

Abstract: BACKGROUND: Bone morphogenetic protein 2 (BMP-2) can promote osteogenesis, and osteocytes secrete sclerostin by expressing SOST gene to inhibit the osteogenic effect of osteoblasts. Some studies have found that BMPs family can promote the secretion of osteosclerotic protein when directly acting on osteocytes, but this contradicts the positive osteogenic effect of BMPs.
OBJECTIVE: To explore the mechanism of BMP-2 indirectly regulating the expression of sclerostin gene in osteocytes.
METHODS: Mouse MC-3T3-E1 cells were treated with different concentrations of BMP-2 (4, 8, 16, 32, 64, 125, 250, 500 and 1 000 μg/L) in vitro. The best concentration of BMP-2 to promote the proliferation of MC-3T3-E1 cells was detected by cell counting kit-8. Then the effect of BMP-2 on the indirect regulation of sclerostin gene expression in osteocytes was studied by co-culture of MC-3T3-E1 cells and MLO-Y4 cells. The possible altered genes in MC-3T3-E1 cells were detected by RT-PCR, and the target genes of MC-3T3-E1 cells were screened to verify the effect of target genes on the expression of sclerostin in MLO-Y4 cells.
RESULTS AND CONCLUSION: BMP-2 could significantly promote the proliferation of osteoblasts. Compared with other concentrations, 250 μg/L had the best effect. The results of RT-PCR experiment showed that BMP-2 could indirectly regulate the expression of sclerostin gene and promote the down-regulation of sclerostin expression in osteocytes (P < 0.01). The results of target gene screening showed that, compared with other genes, the expression of receptor activator of nuclear factor-κB ligand in osteoblasts was significantly downregulated and the expression of osteoprotegerin in osteoblasts was significantly upregulated (P < 0.01). The results of target gene verification showed that BMP-2 may indirectly affect the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand in osteocytes, and then affect the expression of sclerostin in MLO-Y4 cells, thus positively promoting osteogenesis.

Key words: Sclerostin, SOST, bone morphogenetic protein 2, osteocyte, osteoblast

CLC Number:

Tian Zhuang, Wang Diaodiao, Zhang Chu, Li Hanchen, Zhou Jian, Yao Qi. The mechanism by which bone morphogenetic protein 2 indirectly regulates sclerostin expression in osteocytes[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(11): 1686-1691.

Figures/Tables 8

References

[1] JOHNSTON CB, DAGAR M. Osteoporosis in Older Adults. Med Clin North Am. 2020;104(5):873-884.
[2] COTTS KG, CIFU AS. Treatment of Osteoporosis. JAMA. 2018;319(10): 1040-1041.
[3] ENSRUD KE, CRANDALL CJ. Osteoporosis. Ann Intern Med. 2017;167(3): 17-32.
[4] LORENTZON M. Treating osteoporosis to prevent fractures: current concepts and future developments. J Intern Med. 2019;285(4):381-394.
[5] LIU Y, YU P, PENG X, et al. Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis. J Control Release. 2019;304:39-50.
[6] TANAKA S, MATSUMOTO T. Sclerostin: from bench to bedside. J Bone Miner Metab. 2020 Nov 18. doi: 10.1007/s00774-020-01176-0.
[7] FABRE S, FUNCK-BRENTANO T, COHEN-SOLAL M. Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases. J Clin Med. 2020; 9(11):3439.
[8] 章暐, 邹剑, 张长青. 骨硬化蛋白与绝经后妇女脆性骨折的相关性 [J]. 第二军医大学学报,2017,38(9):1206-1210.
[9] DEAN DB, WATSON JT, JIN W, et al. Distinct functionalities of bone morphogenetic protein antagonists during fracture healing in mice. J Anat. 2010;216(5):625-630.
[10] HASHIMOTO K, KAITO T, FURUYA M, et al. In vivo dynamic analysis of BMP-2-induced ectopic bone formation. Sci Rep. 2020;10(1):4751.
[11] ZHANG Y, YANG W, DEVIT A, et al. Efficiency of coculture with angiogenic cells or physiological BMP-2 administration on improving osteogenic differentiation and bone formation of MSCs.J Biomed Mater Res A. 2019;107(3):643-653.
[12] SIMPSON AH, MILLS L, NOBLE B. The role of growth factors and related agents in accelerating fracture healing. J Bone Joint Surg Br. 2006;88(6): 701-705.
[13] LIU DB, SUI C, WU TT, et al. Association of Bone Morphogenetic Protein (BMP)/Smad Signaling Pathway with Fracture Healing and Osteogenic Ability in Senile Osteoporotic Fracture in Humans and Rats. Med Sci Monit. 2018;24:4363-4371.
[14] MAJIDINIA M, SADEGHPOUR A, YOUSEFI B. The roles of signaling pathways in bone repair and regeneration. J Cell Physiol. 2018;233(4): 2937-2948.
[15] KAMIYA N, YE L, KOBAYASHI T, et al. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development. 2008;135(22):3801-3811.
[16] KAMIYA N, KOBAYASHI T, MOCHIDA Y, et al. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res. 2010;25(2):200-210.
[17] KAMIYA N, ATSAWASUWAN P, JOINER DM, et al. Controversy of physiological vs. pharmacological effects of BMP signaling: Constitutive activation of BMP type IA receptor-dependent signaling in osteoblast lineage enhances bone formation and resorption, not affecting net bone mass. Bone. 2020;138:115513.
[18] SEDAGHATI B, JAHROOMISHIRAZI R, STARKE A, et al. Rat Osteosarcoma Cells as a Therapeutic Target Model for Osteoregeneration via Sclerostin Knockdown. Cells Tissues Organs. 2016;201(5):366-379.
[19] 赵明月, 高永红. 老年糖尿病患者饮食对骨质疏松症发生的影响 [J]. 中国现代医药杂志,2020,22(2):47-49.
[20] 洪维, 郑松柏, 李慧林,等. 骨折风险评估工具FRAX?评分判定上海社区老年人群实际骨质疏松性椎体骨折(OVF)效用的研究[J]. 复旦学报(医学版),2020,47(1):83-88+100.
[21] MACÍAS I, ALCORTA-SEVILLANO N, RODRÍGUEZ CI, et al. Osteoporosis and the Potential of Cell-Based Therapeutic Strategies. Int J Mol Sci. 2020;21(5):1653.
[22] ZHANG N, ZHANG ZK, YU Y, et al. Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL. Aptamer Therapy. Front Cell Dev Biol. 2020;8:325.
[23] ROCHEFORT GY, PALLU S, BENHAMOU CL. Osteocyte: the unrecognized side of bone tissue. Osteoporos Int. 2010;21(9):1457-1469.
[24] BELLIDO T. Osteocyte-driven bone remodeling. Calcif Tissue Int. 2014; 94(1):25-34.
[25] CHEN D, ZHAO M, MUNDY GR. Bone morphogenetic proteins. Growth Factors. 2004;22(4):233-241.
[26] TU X, DELGADO-CALLE J, CONDON KW, et al. Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone. Proc Natl Acad Sci U S A. 2015;112(5):E478-486.
[27] TRESGUERRES FGF, TORRES J, LÓPEZ-QUILES J, et al. The osteocyte: A multifunctional cell within the bone. Ann Anat. 2020;227:151422.
[28] TSUKASAKI M, TAKAYANAGI H. Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. Nat Rev Immunol. 2019;19(10):626-642.
[29] DIVIETI PAJEVIC P, KRAUSE DS. Osteocyte regulation of bone and blood. Bone. 2019;119:13-18.
[30] SALAZAR VS, GAMER LW, ROSEN V. BMP signalling in skeletal development, disease and repair. Nat Rev Endocrinol. 2016;12(4):203-221.
[31] DUMIC-CULE I, PERIC M, KUCKO L, et al. Bone morphogenetic proteins in fracture repair. Int Orthop. 2018;42(11):2619-2626.
[32] LI P, BAI Y, YIN G, et al. Synergistic and sequential effects of BMP-2, bFGF and VEGF on osteogenic differentiation of rat osteoblasts. J Bone Miner Metab. 2014;32(6):627-635.
[33] HE G, SHI Y, LIM J, et al. Differential involvement of Wnt signaling in Bmp regulation of cancellous versus periosteal bone growth. Bone Res. 2017;5:17016.
[34] MALIK Z, ALEXIOU M, HALLGRIMSSON B, et al. Bone Morphogenetic Protein 2 Coordinates Early Tooth Mineralization. J Dent Res. 2018; 97(7):835-843.
[35] KONG YY, YOSHIDA H, SAROSI I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315-323.
[36] UDAGAWA N, KOIDE M, NAKAMURA M, et al. Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab. 2021; 39(1):19-26.
[37] ANDERSEN TL, ABDELGAWAD ME, KRISTENSEN HB, et al. Understanding coupling between bone resorption and formation: are reversal cells the missing link. Am J Pathol. 2013;183(1):235-246.
[38] BOYCE BF, XING L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473(2):139-146.
[39] BARON R, KNEISSEL M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2): 179-192.
[40] GLASS DA 2ND, BIALEK P, AHN JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8(5):751-764.
[41] KRAMER I, HALLEUX C, KELLER H, et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010; 30(12):3071-3085.
[42] WEITZMANN MN. Bone and the Immune System. Toxicol Pathol. 2017; 45(7):911-924.